Background: The Unseen Gap in Consumer Hardware Investment
For years, the global investment community has focused heavily on a narrow band of consumer hardware: smartphones,...
China Strategy analysis for foreign businesses in China — A deep dive into how multinational enterprises can replicate systematic project execution in complex regulatory...
Case Study: How a German MedTech Firm Achieved 78% Faster Regulatory Approval Through a Localized Joint Venture
Background
In early 2024, a mid-sized German medical device...
A definitive China Strategy analysis for foreign businesses seeking profitable market entry. As the Chinese economy transitions from high-speed growth to high-quality development, the...
China eliminated minimum registered capital requirements, but practical requirements remain. Understand how much capital to inject, when, and in what form.
China's pharmaceutical sector is shifting from generics to first-in-class drugs, with $18.3 billion in out-licensing deals in H1 2026. But U.S. regulatory scrutiny is reshaping deal terms and timelines.